Infliximab monotherapy in psoriasis: A case of rapid clinical and histological response

International Journal of Dermatology

Volumn 43, Issue 4, 2004, Pages 303-308

  Vincek, V ^a   Jacob, S E ^a   Nassiri, M ^a   Herbert, L M ^a   Nadji, M ^a   Kerdel, Francisco A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLONAZEPAM; CYCLOSPORIN; ETRETIN; ETRETINATE; FLUOCINONIDE; GABAPENTIN; HYDROCORTISONE; INFLIXIMAB; KI 67 ANTIGEN; METHOTREXATE; PAROXETINE; TEMAZEPAM; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; GENETIC PREDISPOSITION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; KERATINOCYTE; LYMPHOCYTE; MALE; MONOTHERAPY; NEUTROPHIL; PATHOGENESIS; PSORIASIS;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; KERATINOCYTES; KI-67 ANTIGEN; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PSORIASIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2342437768     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.01961.x     Document Type: Article

References (17)

1. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumor necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
2. Kirby B, Marsland AM, Carmichael AJ, et al. Successful treatment of severe recalcitrant psoriasis with combination Infliximab and methotrexate. Clin Exp Dermatol 2001; 26: 27-29.
3. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-426.
4. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of Infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-1847.
5. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077-1081.
6. Van Deventer SJH. Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001; 121: 1242-1246.
7. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-1157.
8. Agnholt J, Kaltoft K. Infliximab downregulates IFN-γ production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001; 15: 212-222.
9. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002; 41: 449-452.
10. Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol 1992; 26: 779-780.
11. Nadji M, Nassiri M, Fresno M, et al. Laminin receptor in lymph node negative breast carcinoma. Cancer 1999; 85: 432-436.
12. Hitchcock CH. Ki-67 staining as a means to simplify analysis of tumor cell proliferation. Am J Clin Pathol 96: 444-446.
13. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 2001 October; 19: 617-35.
14. Taylor PC, Peters AM, Paleolong E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 38-47.
15. Scallon BJ, Arevlo MM, Trinh H, et al. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine 1995; 7: 251-259.
16. Mease PH, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trail. Lancet 2000; 356: 385-390.
17. Schon M, Denzer D, Kubitza RC, et al. Critical role of neutrophils for the generation of psoriaform skin lesions in flaky skin mice. J Invest Dermatol 2000; 114: 976-983.